Vikas Dandekar on Muck Rack

Vikas Dandekar

Verified
  • Editor, Pharma and Life Science, ET Prime
Mumbai
As seen in: ET Prime, 7@7, Ahmedabad Mirror, Bangalore Mirror, ET Healthworld, ETTech.com, The Economic Times, The Times of India, India Times, Flipboard, Moneycontrol and
Journalist - Indian pharma & healthcare. Views own vikas.dandekar@timesofindia.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vikas

Contact Vikas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Novo Nordisk Readies Once-Weekly Insulin Shot for Indian Market

|
By Rica Bhattacharyya Verified, Vikas Dandekar Verified
| The Economic Times Verified
India has approved Awiqli for adults with both Type 1 and 2 diabetes, broader than the current US approval, which is only for use in Type 2 diabetes patients. MumbaI: Danish pharma giant Novo Nordisk is set to launch the world's first once-weekly insulin brand Awiqli ( insulin icodec) in India, making the country one of its earliest target markets.
Open in Who Shared View Duplicates (5) Issue with article?

Retatrutide: Can this shot make you lose weight & live longer, too?

|
By Vikas Dandekar Verified
| The Economic Times Verified
Eli Lilly is studying retatrutide in several phase-3 clinical trials for obesity, type-2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatosis liver disease. Social media has been abuzz about retatrutide, a weight-loss drug that is in late clinical trials but is already being seen by medical experts as the next big leap in the treatment of diabetes and obesity.
Open in Who Shared View Duplicates (5) Issue with article?

With sights on huge gains, Biocon to scale up AI focus

|
By Vikas Dandekar Verified, Rica Bhattacharyya Verified
| The Economic Times Verified
The company's planned AI scale-up in procurement and R&D will lead to significant cost saving as well as improve drug development timeline and also improve topline in the next 3-4 years, chief technology officer Mandar Ghatnekar told ET.
Open in Who Shared View Duplicates (5) Issue with article?
See all 982 licensed articles (1,463 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified